Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

EXAS

Exact Sciences Corp

Feb 13 • 04:00PM ET

103.24

+0.01 0.01 %

Healthcare • Diagnostics & Research • USA • NASD

Feb 13, 7:15 PMExact Sciences reports fiscal Q4 2025 results with non-GAAP EPS -$0.45 (+90% YoY) missing estimates and revenue $878.4M (+23% YoY) beating estimates, posts record Q4 revenue and FY 2025 revenue of $3.25B, and reiterates progress toward its pending Abbott acquisition.

Peers: ILMN GH NTRA TXG DGX FLGT BIO QDEL MYGN CSTM

| Held by: VTI VB VBK VXF XBI FBT IWR VHT SCHM IWD

Index	-	P/E	-	EPS (ttm)	-1.10	Insider Own	1.93%	Shs Outstand	190.80M	Perf Week	0.06%
Market Cap	19.70B	Forward P/E	84.19	EPS next Y	1.23	Insider Trans	-0.70%	Shs Float	187.13M	Perf Month	0.96%
Enterprise Value	21.27B	PEG	-	EPS next Q	-0.18	Inst Own	88.11%	Short Float	3.55%	Perf Quarter	51.00%
Income	-207.95M	P/S	6.07	EPS this Y	126.94%	Inst Trans	-12.07%	Short Ratio	1.27	Perf Half Y	129.47%
Sales	3.25B	P/B	8.20	EPS next Y	313.76%	ROA	-3.39%	Short Interest	6.65M	Perf YTD	1.65%
Book/sh	12.58	P/C	20.42	EPS next 5Y	-	ROE	-8.66%	52W High	103.54 -0.29%	Perf Year	104.07%
Cash/sh	5.06	P/FCF	55.21	EPS past 3/5Y	32.20% 27.36%	ROIC	-4.25%	52W Low	38.81 166.00%	Perf 3Y	57.84%
Dividend Est.	-	EV/EBITDA	322.75	Sales past 3/5Y	15.92% 16.84%	Gross Margin	69.69%	Volatility	0.25% 0.33%	Perf 5Y	-33.40%
Dividend TTM	-	EV/Sales	6.55	EPS Y/Y TTM	-353.69%	Oper. Margin	-4.79%	ATR (14)	0.41	Perf 10Y	1658.77%
Dividend Ex-Date	-	Quick Ratio	2.17	Sales Y/Y TTM	17.69%	Profit Margin	-6.40%	RSI (14)	73.44	Recom	2.81
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	90.29%	SMA20	0.56%	Beta	1.41	Target Price	104.00
Payout	-	Debt/Eq	1.06	Sales Q/Q	23.12%	SMA50	1.16%	Rel Volume	0.41	Prev Close	103.23
Employees	7200	LT Debt/Eq	1.04	Earnings	Feb 13 AMC	SMA200	50.91%	Avg Volume	5.22M	Price	103.24
IPO	Jan 31, 2001	Option/Short	Yes / Yes	EPS/Sales Surpr.	-317.05% 2.03%	Trades		Volume	2,120,491	Change	0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-20-26	Downgrade	Mizuho	Outperform → Neutral	$105
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line	$105
Apr-10-25	Initiated	Mizuho	Outperform	$60
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$52
Jan-23-25	Initiated	Barclays	Overweight	$70
Aug-28-24	Initiated	Wells Fargo	Overweight	$75
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$70
Jun-03-24	Resumed	Jefferies	Buy	$75
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy	$91
Dec-14-23	Initiated	Guggenheim	Buy	$90
Dec-13-23	Initiated	Wolfe Research	Outperform	$95
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$90
Sep-28-23	Initiated	Bernstein	Outperform	$83
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy	$55 → $85
May-05-23	Initiated	UBS	Neutral	$73
Mar-09-23	Upgrade	Citigroup	Neutral → Buy	$70 → $90
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$50 → $70
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold	$60 → $35

Show Previous Ratings

Today 11:40AM	CSLLY vs. EXAS: Which Stock Is the Better Value Option? (Zacks)
Feb-13-26 05:15PM	Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Exact Sciences: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results (Business Wire)
Feb-12-26 01:04PM	Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next? (24/7 Wall St.)
11:01AM	Loading…
Feb-09-26 11:01AM	Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. (Barrons.com)
Feb-08-26 11:04PM	Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Feb-06-26 05:41PM	Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. (Barrons.com)
Feb-03-26 02:32PM	Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests (Business Wire)
09:03AM	Oncotype DX Breast Recurrence Score Test Surpasses 2 Million Patients Worldwide (Business Wire)
08:30AM	Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025 (Insider Monkey)
Feb-02-26 12:05PM	The Best Dividend King to Buy With $150 (Motley Fool)
Jan-28-26 06:46AM	Medtech M&A took off in the second half of 2025: report (MedTech Dive)
Jan-27-26 11:40AM	EXEL vs. EXAS: Which Stock Is the Better Value Option? (Zacks)
07:46AM	Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement (Insider Monkey)
06:40AM	Loading…
Jan-26-26 06:40AM	3 Reasons to Buy This Dividend King After Its Steep Sell-Off (Motley Fool)
Jan-22-26 04:02PM	Abbott Falls Most in Nearly 24 Years on Formula Pricing Stumble (Bloomberg)
04:01PM	Abbott Laboratories (ABT) Q4 2025 Earnings Call Highlights: Navigating Market Challenges with ... (GuruFocus.com)
02:16PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
09:48AM	Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints (Benzinga)
08:53AM	Abbott Tumbles On Disappointing Fourth Quarter As Exact Closing Looms (Investor's Business Daily)
Jan-20-26 08:47AM	Exact Sciences (EXAS) Rose Following the Acquisition Announcement by Abbott (Insider Monkey)
07:55AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Chevron, Dominos Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More (24/7 Wall St.)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 07:51AM	Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold? (Zacks)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire)
12:48PM	Halper Sadeh LLC Encourages FRGE, EXAS, CIVI, KVUE Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
12:21PM	CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois (Zacks)
Jan-07-26 12:31PM	Select Medical Expands Rehab Footprint Through Vibra Healthcare JV (Zacks)
11:52AM	Loading…
11:52AM	ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies (Zacks)
11:49AM	JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus (Zacks)
Jan-06-26 11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks)
11:00AM	Halper Sadeh LLC Encourages EXAS, SOAR, BTBD Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-04-26 11:32PM	1 High-Flying Stock on Our Watchlist and 2 We Question (StockStory)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
07:32AM	How Tempus AI Is Building Scale While Near-Term Risks Persist (Zacks)
Dec-26-25 01:48PM	Moderna Stock Sees Healthy Relative Strength Rating (Investor's Business Daily)
Dec-16-25 02:09PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-15-25 02:59PM	Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Dec-11-25 05:30PM	Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect MRD Test in Early Triple-Negative Breast Cancer at SABCS (Business Wire)
Dec-10-25 11:35PM	1 Healthcare Stock for Long-Term Investors and 2 We Avoid (StockStory)
Dec-08-25 01:35AM	Freenome inks deals to list stock and raise $330M (MedTech Dive)
Dec-05-25 09:41AM	Tempus AI: Revenue Mix and 2026 Growth Outlook Explained (Zacks)
Dec-03-25 11:30AM	Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? (Zacks)
Dec-02-25 04:54AM	Here's Why Grail Soared, Again, in November (Motley Fool)
Dec-01-25 12:33PM	Cathie Wood dumps $8.46 million in software giant (TheStreet)
Nov-30-25 02:05AM	This Top Dividend King Just Became an Even Better Buy (Motley Fool)
Nov-28-25 12:41PM	Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-25-25 09:36AM	Brinker upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More (24/7 Wall St.)
01:33AM	Halper Sadeh LLC Encourages GDOT, BLFY, EXAS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-24-25 04:35PM	Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium (Business Wire)
09:41AM	Booking, Carvana upgraded: Wall Street's top analyst calls (The Fly)
09:20AM	Here are Mondays Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More (24/7 Wall St.)
Nov-23-25 10:30PM	Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks (StockStory)
Nov-21-25 09:10AM	Here Are Fridays Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More (24/7 Wall St.)
07:32AM	Health Care Roundup: Market Talk (The Wall Street Journal)
06:30AM	Abbott Breaks into Lucrative Cancer Screening Market with $21 Billion Exact Sciences Purchase (The Daily Upside)
04:50AM	Abbott to acquire all outstanding shares in Exact Sciences (Medical Device Network)
03:35AM	Stock Market Today: Dow Futures Inch Up; Bitcoin Slides; VIX Jumps (The Wall Street Journal)
Nov-20-25 07:50PM	Halper Sadeh LLC Encourages CIVI, JAMF, EXAS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire) +16.81%
07:43PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
06:29PM	Why the Stock Price of This Cancer Screening Company Soared 17% Thursday (Investopedia)
05:06PM	Health Care Roundup: Market Talk (The Wall Street Journal)
05:05PM	Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
04:44PM	Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More (Motley Fool)
04:23PM	These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More (Barrons.com)
04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
04:14PM	Exact Sciences Catapults On $23 Billion Abbott Labs Buyout (Investor's Business Daily)
03:31PM	Why Exact Sciences Rallied Over 50% This Week (Motley Fool)
03:08PM	Abbott Laboratories announces $21 billion deal to buy Cologuard-maker Exact Sciences (Chicago Tribune)
03:03PM	Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here? (Barchart)
03:01PM	Why Exact Sciences Stock Surged Today (Motley Fool)
02:47PM	These Stocks Are Moving the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More (Barrons.com)
01:36PM	Stocks to Watch Thursday: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
01:02PM	Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More (Investopedia)
12:01PM	Madison's Exact Sciences' $23 billion sale is tied to its Cologuard cancer test. What to know (Milwaukee Journal Sentinel)
11:51AM	Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion (Barrons.com)
11:32AM	What to know about Exact Sciences. The Madison company was sold to Abbot for $23 billion. (Milwaukee Journal Sentinel)
10:21AM	Exact Sciences Soars As Abbott Unveils $21 Billion Buyout (GuruFocus.com)
09:41AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences (The Wall Street Journal)
09:31AM	Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences (Financial Times)
09:26AM	Abbott to buy Exact Sciences for $21B, Verizon to cut 13K jobs (Yahoo Finance Video)
08:43AM	Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test (MarketWatch)
08:09AM	Exact Sciences stock jumps after Abbott confirms acquisition (Investing.com)
07:46AM	Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. (Barrons.com)
07:46AM	Abbott to Acquire Exact Sciences for $21 Billion (The Wall Street Journal)
07:30AM	Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments (PR Newswire)
06:27AM	Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports (Insider Monkey)
Nov-19-25 07:21PM	Why Exact Sciences Stock Blasted Nearly 24% Higher Today (Motley Fool) +23.68%
04:57PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
04:31PM	Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories Buyout (Investor's Business Daily)
04:27PM	Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories (Barrons.com)
02:36PM	Exact Sciences shares soar on report Abbott is nearing deal for the company (Investing.com)
11:19AM	Stock Market Today: Fed Minutes Weigh on U.S. Equities As Traders Await News (TheStreet)
06:22AM	Freenome and Roche partner on cancer screening technology for ex-US markets (Medical Device Network)
Nov-17-25 01:13PM	Molina Secures Deal From AHCA to Serve Florida's Medicaid Members (Zacks)
Nov-15-25 09:00AM	Alphabets Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too? (24/7 Wall St.)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORVILLE JACOB A	EVP, GM, Screening	Dec 23 '25	Option Exercise	0.00	73,080	0	69,511	Dec 30 04:30 PM
Baranick Brian	EVP, GM, Precision Oncology	Dec 23 '25	Option Exercise	0.00	73,080	0	66,487	Dec 30 04:30 PM
Condella Sarah	EVP, Human Resources	Dec 23 '25	Option Exercise	0.00	47,208	0	118,059	Dec 30 04:30 PM
Herriott James	SVP, General Counsel & Sec	Dec 23 '25	Option Exercise	0.00	33,780	0	32,934	Dec 30 04:30 PM
Bloomer Aaron	EVP, Chief Financial Officer	Dec 23 '25	Option Exercise	0.00	63,099	0	59,571	Dec 30 04:30 PM
ORVILLE JACOB A	EVP, GM, Screening	Nov 19 '25	Sale	75.00	5,000	375,000	23,237	Nov 21 05:30 PM
Herriott James	SVP, General Counsel & Sec	Nov 19 '25	Sale	70.00	1,000	70,000	11,585	Nov 21 05:30 PM
ORVILLE JACOB A	Officer	Nov 19 '25	Proposed Sale	75.00	5,000	375,000		Nov 19 03:11 PM
Herriott James	Officer	Nov 19 '25	Proposed Sale	70.00	1,000	70,000		Nov 19 12:04 PM
Herriott James	SVP, General Counsel & Sec	Nov 04 '25	Sale	70.08	1,500	105,120	12,585	Nov 06 05:29 PM
Baranick Brian	EVP, GM, Precision Oncology	Nov 04 '25	Sale	70.08	2,858	200,289	22,368	Nov 06 05:29 PM
Baranick Brian	Officer	Nov 04 '25	Proposed Sale	70.08	2,858	200,289		Nov 04 10:25 AM
Herriott James	Officer	Nov 04 '25	Proposed Sale	70.08	1,500	105,120		Nov 04 10:22 AM
Zanotti Katherine S	Director	Oct 24 '25	Sale	65.00	12,000	780,000	60,759	Oct 27 08:35 PM
Zanotti Katherine S	Director	Oct 24 '25	Proposed Sale	65.00	12,000	780,000		Oct 24 11:08 AM
Herriott James	SVP, General Counsel & Sec	Oct 09 '25	Sale	60.00	1,500	90,000	14,085	Oct 10 05:27 PM
Doyle James Edward	Director	Oct 09 '25	Sale	60.00	2,000	120,000	57,962	Oct 10 05:25 PM
Herriott James	Officer	Oct 09 '25	Proposed Sale	60.00	1,500	90,000		Oct 09 11:23 AM
Doyle James Edward	Director	Oct 09 '25	Proposed Sale	60.00	2,000	120,000		Oct 09 11:18 AM
Doyle James Edward	Director	Aug 13 '25	Sale	42.02	1,485	62,400	59,962	Aug 14 04:30 PM
Doyle James Edward	Director	Aug 13 '25	Proposed Sale	42.02	1,485	62,400		Aug 13 10:09 AM
ORVILLE JACOB A	EVP, GM, Screening	Aug 05 '25	Option Exercise	0.00	5,350	0	30,752	Aug 07 05:30 PM
Baranick Brian	EVP, GM, Precision Oncology	Aug 05 '25	Option Exercise	0.00	5,350	0	27,943	Aug 07 05:30 PM
Sebelius Kathleen	Former Director	Jul 16 '25	Proposed Sale	53.11	8,164	433,605		Jul 16 04:22 PM
Zanotti Katherine S	Director	Jun 13 '25	Sale	53.20	3,207	170,612	72,759	Jun 16 05:30 PM
Zanotti Katherine S	Director	Jun 13 '25	Proposed Sale	53.20	3,207	170,612		Jun 13 09:50 AM
Bloomer Aaron	EVP, Chief Financial Officer	Apr 15 '25	Option Exercise	0.00	24,460	0	19,340	Apr 17 04:30 PM
Conroy Kevin T	President and CEO	Mar 07 '25	Option Exercise	22.38	66,723	1,493,261	1,203,269	Mar 10 05:00 PM
Herriott James	SVP, General Counsel & Sec	Feb 28 '25	Option Exercise	0.00	4,265	0	16,339	Mar 04 04:48 PM
Conroy Kevin T	President and CEO	Feb 28 '25	Option Exercise	0.00	40,310	0	1,146,965	Mar 04 04:47 PM
Baranick Brian	EVP, GM, Precision Oncology	Feb 28 '25	Option Exercise	0.00	9,673	0	25,106	Mar 04 04:44 PM
ORVILLE JACOB A	EVP, GM, Screening	Feb 28 '25	Option Exercise	0.00	9,673	0	27,728	Mar 04 04:40 PM
Condella Sarah	EVP, Human Resources	Feb 28 '25	Option Exercise	0.00	7,738	0	84,399	Mar 04 04:37 PM
Condella Sarah	EVP, Human Resources	Feb 25 '25	Option Exercise	0.00	3,954	0	80,297	Feb 26 08:00 PM
Baranick Brian	EVP, GM, Precision Oncology	Feb 25 '25	Option Exercise	0.00	3,954	0	19,841	Feb 26 08:00 PM
Herriott James	SVP, General Counsel & Sec	Feb 25 '25	Option Exercise	0.00	1,647	0	13,738	Feb 26 08:00 PM
ORVILLE JACOB A	EVP, GM, Screening	Feb 25 '25	Option Exercise	0.00	3,954	0	22,136	Feb 26 08:00 PM
Conroy Kevin T	President and CEO	Feb 25 '25	Option Exercise	0.00	13,180	0	1,121,378	Feb 26 08:00 PM
Conroy Kevin T	President and CEO	Feb 19 '25	Option Exercise	0.00	10,374	0	1,084,565	Feb 21 04:30 PM
COWARD D SCOTT	Director	Feb 19 '25	Option Exercise	0.00	2,248	0	52,831	Feb 21 04:30 PM
ORVILLE JACOB A	EVP, GM, Screening	Feb 19 '25	Option Exercise	0.00	2,248	0	16,688	Feb 21 04:30 PM
Baranick Brian	EVP, GM, Precision Oncology	Feb 19 '25	Option Exercise	0.00	1,729	0	14,487	Feb 21 04:30 PM
Condella Sarah	EVP, Human Resources	Feb 19 '25	Option Exercise	0.00	2,248	0	74,859	Feb 21 04:30 PM
Herriott James	SVP, General Counsel & Sec	Feb 19 '25	Option Exercise	0.00	865	0	10,731	Feb 21 04:30 PM

Open in Screener

NVCR

NovoCure Ltd

Feb 13 • 04:00PM ET

10.99

-1.54 -12.29 %

Healthcare • Medical Devices • United Kingdom • NASD

Peers: MDT BSX EW ISRG ZBH SYK TFX ALGN PEN RMD

| Held by: VTI VB IWM VBK VXF IWO IBB VTWO SCHA IHI

Index	RUT	P/E	-	EPS (ttm)	-1.61	Insider Own	10.00%	Shs Outstand	111.98M	Perf Week	8.38%
Market Cap	1.23B	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.73%	Shs Float	100.78M	Perf Month	-20.19%
Enterprise Value	992.58M	PEG	-	EPS next Q	-0.41	Inst Own	85.69%	Short Float	7.91%	Perf Quarter	-3.26%
Income	-177.65M	P/S	1.92	EPS this Y	10.17%	Inst Trans	2.03%	Short Ratio	4.45	Perf Half Y	-5.18%
Sales	642.27M	P/B	3.61	EPS next Y	-13.94%	ROA	-13.75%	Short Interest	7.97M	Perf YTD	-15.00%
Book/sh	3.05	P/C	1.19	EPS next 5Y	7.48%	ROE	-50.60%	52W High	22.95 -52.11%	Perf Year	-49.38%
Cash/sh	9.25	P/FCF	-	EPS past 3/5Y	-40.48% -83.87%	ROIC	-30.70%	52W Low	9.82 11.91%	Perf 3Y	-87.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.19% 11.49%	Gross Margin	75.52%	Volatility	11.32% 6.67%	Perf 5Y	-94.21%
Dividend TTM	-	EV/Sales	1.55	EPS Y/Y TTM	-15.64%	Oper. Margin	-27.37%	ATR (14)	1.00	Perf 10Y	-9.25%
Dividend Ex-Date	-	Quick Ratio	1.50	Sales Y/Y TTM	11.17%	Profit Margin	-27.66%	RSI (14)	42.24	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	-17.92%	SMA20	-9.12%	Beta	0.72	Target Price	25.21
Payout	-	Debt/Eq	2.34	Sales Q/Q	7.81%	SMA50	-14.06%	Rel Volume	1.99	Prev Close	12.53
Employees	1488	LT Debt/Eq	0.70	Earnings	Feb 26 BMO	SMA200	-21.52%	Avg Volume	1.79M	Price	10.99
IPO	Oct 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.37% 5.20%	Trades		Volume	3,568,545	Change	-12.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$14.50
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$30
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98

Show Previous Ratings

Feb-13-26 07:42AM	Novocures stock rises 37% on FDA clearance of pancreatic cancer treatment device (Medical Device Network) -12.29%
06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
Feb-12-26 05:43PM	Novocure Is Up 19%. FDA Approval Is Giving the Biotech Stock a Lift. (Barrons.com) +19.33%
04:35PM	These Stocks Are Todays Movers: AppLovin, Fastly, Micron, Cisco, QuantumScape, Novocure, AST SpaceMobile, and More (Barrons.com)
04:15PM	Stocks to Watch Thursday Recap: Cisco, McDonalds, AppLovin (The Wall Street Journal)
03:11PM	Loading…
03:11PM	Stock Market Today: S&P 500 Breaks Key Support As Techs Pace Sell-Off; Cancer Stock Vaults (Live Coverage) (Investor's Business Daily)
11:26AM	NovoCure Stock Surges After FDA Approves Optune Pax (Benzinga)
10:07AM	Stocks to Watch Thursday: Cisco, McDonald's, AppLovin (The Wall Street Journal)
06:53AM	This Biotech Stock Is Jumping 25% After Getting an FDA Boost (Barrons.com)
06:28AM	AppLovin shares slide after earnings, and other early market movers (MarketWatch)
06:19AM	Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report-Micron, Novocure, Fastly In Focus (Benzinga)
04:50AM	Stock Market Today: Dow, S&P 500 and Nasdaq point higher as tech finds its footing; Treasurys steady; precious metals dip. (MarketWatch)
Feb-11-26 09:55PM	NovoCure (NVCR) Stock Is Trending Overnight - Here's What You Should Know (Benzinga)
06:33PM	Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar (The Wall Street Journal)
05:54PM	U.S. FDA Approves Novocure's Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer (Business Wire)
08:10AM	Loading…
Feb-05-26 08:10AM	Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates (Zacks) -12.72%
Jan-12-26 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update (Business Wire)
Jan-07-26 03:58AM	Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? (Zacks)
Dec-22-25 07:00AM	Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-09-25 05:31AM	Medtronic changes investor relations leadership ahead of diabetes spinout (MedTech Dive) +5.31%
Dec-01-25 07:00AM	Novocure Appoints Company President Frank Leonard as Chief Executive Officer (Business Wire) -8.82%
Nov-26-25 07:00AM	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-12-25 10:00AM	2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon (Motley Fool)
07:00AM	Novocure to Participate in 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-30-25 04:22PM	NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
10:30AM	Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:17AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-15-25 07:00AM	Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress (Business Wire) +7.67%
07:00AM	Loading…
Oct-01-25 07:00AM	Novocure to Report Third Quarter 2025 Financial Results (Business Wire) +8.20%
Sep-29-25 04:30PM	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting (Business Wire)
Sep-16-25 05:28AM	Novocure obtains approval for Optune Lua device in Japan to treat NSCLC (Medical Device Network)
Sep-15-25 07:00AM	Novocure's Optune Lua Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
Aug-29-25 04:26AM	2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts (Motley Fool)
Aug-28-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
Aug-25-25 07:00AM	Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain (Business Wire) -5.87%
Aug-22-25 01:37PM	NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer (Zacks)
Aug-20-25 07:00AM	Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer (Business Wire)
Aug-13-25 12:08PM	Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) (Insider Monkey)
Jul-25-25 07:02AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 01:30PM	NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -24.05%
08:05AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Novocure Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-01-25 07:00AM	Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 (Business Wire)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
07:00AM	Novocure to Report Second Quarter 2025 Financial Results (Business Wire)
Jun-18-25 12:00PM	What Makes NovoCure (NVCR) a New Buy Stock (Zacks)
Jun-06-25 12:26PM	NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial (Zacks)
Jun-02-25 02:05PM	NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial (Benzinga) -10.83%
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
08:00AM	Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-28-25 06:57AM	1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
May-27-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
May-16-25 10:00AM	The Next Frontier to Treat Cancer: Electricity (The Wall Street Journal)
May-15-25 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? (Zacks)
Apr-29-25 09:55AM	Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? (Zacks)
Apr-25-25 01:21PM	Why NovoCure Stock Skyrocketed This Week (Motley Fool)
Apr-24-25 07:03PM	Why NovoCure Stock Leaped 4% Higher Today (Motley Fool)
10:34AM	NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 10:16AM	Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire) +7.63%
06:45AM	Novocures device for metastatic NSCLC treatment gains CE Mark (Medical Device Network)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks) +5.97%
07:09AM	Novocure's Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Apr-17-25 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-16-25 03:43PM	Why NovoCure Stock Was Withering on Wednesday (Motley Fool)
Apr-10-25 08:40AM	Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? (Zacks) -5.13%
Apr-01-25 07:00AM	Novocure to Report First Quarter 2025 Financial Results (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha)
Mar-04-25 07:00AM	Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference (Business Wire)
Feb-28-25 02:09AM	NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com)
Feb-27-25 03:30PM	NovoCure (NVCR) Q4 2024 Earnings Call Transcript (Motley Fool) -12.43%
10:00AM	NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (Business Wire)
Feb-20-25 10:00AM	NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jan-30-25 03:14PM	Jim Cramer on NovoCure Limited (NVCR): I Have Watched Them For Years And Years And Theyre Not Making Money (Insider Monkey)
Jan-22-25 04:00AM	Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland (Business Wire)
Jan-13-25 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update (Business Wire)
Jan-03-25 07:00AM	Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-14-24 06:50AM	Novocure price target raised to $42 from $28 at Piper Sandler (TipRanks)
Dec-06-24 08:32AM	Why NovoCure Stock Was Winning Big This Week (Motley Fool) +5.11%
Dec-05-24 04:29AM	Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? (Motley Fool) -9.00%
Dec-03-24 02:51PM	Novocure Stock Earns 96 RS Rating (Investor's Business Daily)
07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
Dec-02-24 04:23PM	Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds (Investor's Business Daily) +48.95%
01:20PM	Novocure seeks approval after pancreatic cancer wearable scores at Phase III (Clinical Trials Arena)
10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
09:54AM	Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success (GuruFocus.com)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
07:00AM	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
06:08AM	Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date (BioPharma Dive)
Nov-27-24 07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire) +10.12%
Nov-21-24 11:58AM	Novocure secures FDA approval for add-ons to brain cancer treatment wearable (Medical Device Network)
07:05AM	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma (Business Wire)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cordova Ashley	Chief Executive Officer	Sep 05 '25	Buy	12.22	81,550	996,859	437,569	Sep 08 07:10 AM
Brackmann Christoph	Chief Financial Officer	Jul 29 '25	Buy	11.59	20,000	231,800	141,150	Jul 30 04:33 PM
Stafford Kristin	Director	Jun 03 '25	Sale	17.28	999	17,259	3,054	Jun 04 04:26 PM
LEUNG GABRIEL	Director	Jun 03 '25	Sale	17.31	999	17,297	81,229	Jun 04 04:24 PM
Madden Martin J.	Director	Jun 03 '25	Sale	17.19	999	17,176	18,674	Jun 04 04:23 PM
Scannell Timothy J	Director	Jun 03 '25	Sale	17.32	999	17,299	6,018	Jun 04 04:22 PM
HILLEMAN JERYL L	Director	Jun 03 '25	Sale	17.26	999	17,247	5,591	Jun 04 04:17 PM
Ocean Allyson J	Director	Jun 03 '25	Sale	17.29	999	17,269	3,054	Jun 04 04:16 PM
VERNON W ANTHONY	Director	Jun 03 '25	Sale	17.35	999	17,329	167,887	Jun 04 04:14 PM
Hung David	Director	Jun 03 '25	Sale	17.30	999	17,280	12,195	Jun 04 04:11 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Jun 02 '25	Sale	17.50	30,196	528,413	168,452	Jun 04 04:09 PM
FRANCIS LEONARD	Officer	Jun 02 '25	Proposed Sale	19.11	30,196	577,046		Jun 02 04:25 PM
Paravasthu Mukund	Chief Operating Officer	May 03 '25	Sale	17.91	592	10,604	83,556	May 05 04:17 PM
MUKUND PARAVASTHU	Officer	May 05 '25	Proposed Sale	17.91	592	10,604		May 05 04:05 PM
Weinberg Uri	Chief Innovation Officer	Mar 03 '25	Sale	18.92	268	5,071	166,243	Mar 04 04:19 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 03 '25	Sale	18.54	2,527	46,841	143,673	Mar 04 04:19 PM
Cordova Ashley	Chief Executive Officer	Mar 03 '25	Sale	18.54	2,053	38,055	204,005	Mar 04 04:19 PM
Paravasthu Mukund	Chief Operating Officer	Mar 03 '25	Sale	18.54	250	4,634	29,173	Mar 04 04:16 PM
FRANCIS LEONARD	Officer	Mar 03 '25	Proposed Sale	18.54	2,527	46,841		Mar 03 05:34 PM
MUKUND PARAVASTHU	Officer	Mar 03 '25	Proposed Sale	18.54	250	4,634		Mar 03 05:31 PM
URI WEINBERG	Officer	Mar 03 '25	Proposed Sale	18.92	268	5,071		Mar 03 05:20 PM
ASHLEY CORDOVA	Officer	Mar 03 '25	Proposed Sale	18.54	2,053	38,055		Mar 03 05:18 PM
WILHELMUS GROENHUYSEN	Officer	Mar 03 '25	Proposed Sale	18.54	3,165	58,667		Mar 03 05:13 PM
Weinberg Uri	Chief Innovation Officer	Feb 28 '25	Sale	18.75	4,637	86,949	166,511	Mar 03 04:28 PM
Leupin Nicolas	Chief Medical Officer	Feb 27 '25	Sale	20.02	991	19,844	50,133	Mar 03 04:28 PM
Puri Michal Nath	Chief Human Resources Officer	Feb 27 '25	Sale	20.02	1,387	27,773	108,706	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 27 '25	Sale	20.02	12,266	245,609	148,970	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '25	Sale	18.28	2,770	50,648	146,200	Mar 03 04:27 PM
Cordova Ashley	Chief Executive Officer	Feb 27 '25	Sale	20.02	11,153	223,323	208,399	Mar 03 04:26 PM
Cordova Ashley	Chief Executive Officer	Feb 28 '25	Sale	18.28	2,341	42,804	206,058	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 27 '25	Sale	20.02	1,646	32,959	29,791	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 28 '25	Sale	18.28	368	6,729	29,423	Mar 03 04:26 PM
URI WEINBERG	Officer	Feb 28 '25	Proposed Sale	18.75	4,637	86,949		Feb 28 05:01 PM
MUKUND PARAVASTHU	Officer	Feb 28 '25	Proposed Sale	18.28	368	6,729		Feb 28 04:50 PM
ASHLEY CORDOVA	Officer	Feb 28 '25	Proposed Sale	18.28	2,341	42,803		Feb 28 04:43 PM
WILHELMUS GROENHUYSEN	Officer	Feb 28 '25	Proposed Sale	18.28	3,202	58,546		Feb 28 04:40 PM
FRANCIS LEONARD	Officer	Feb 28 '25	Proposed Sale	18.28	2,770	50,647		Feb 28 04:38 PM
MUKUND PARAVASTHU	Officer	Feb 27 '25	Proposed Sale	20.02	1,646	32,959		Feb 27 04:42 PM
ASHLEY CORODVA	Officer	Feb 27 '25	Proposed Sale	20.02	11,153	223,322		Feb 27 04:39 PM
WILHELMUS GROENHUYSEN	Officer	Feb 27 '25	Proposed Sale	20.02	7,211	144,389		Feb 27 04:36 PM
FRANCIS LEONARD	Officer	Feb 27 '25	Proposed Sale	20.02	12,266	245,608		Feb 27 04:28 PM

Open in Screener

PODD

Insulet Corporation

Feb 13 • 04:00PM ET

242.74

+1.92 0.80 %

Healthcare • Medical Devices • USA • NASD

PODD Insulet Corporation daily Stock Chart

Peers: DXCM JNJ ABT MDT EW SYK TNDM BSX BAX LIVN

| Held by: VTI VOO VB IVV VO SPY VUG RSP VBK XLV

Index	S&P 500	P/E	70.43	EPS (ttm)	3.45	Insider Own	0.41%	Shs Outstand	70.35M	Perf Week	0.33%
Market Cap	17.08B	Forward P/E	38.99	EPS next Y	6.23	Insider Trans	-2.25%	Shs Float	70.04M	Perf Month	-14.19%
Enterprise Value	17.35B	PEG	1.12	EPS next Q	1.46	Inst Own	102.36%	Short Float	2.76%	Perf Quarter	-27.94%
Income	246.20M	P/S	6.77	EPS this Y	50.72%	Inst Trans	0.18%	Short Ratio	2.32	Perf Half Y	-23.13%
Sales	2.52B	P/B	12.34	EPS next Y	27.48%	ROA	8.13%	Short Interest	1.93M	Perf YTD	-14.60%
Book/sh	19.68	P/C	22.55	EPS next 5Y	34.68%	ROE	19.68%	52W High	354.88 -31.60%	Perf Year	-13.96%
Cash/sh	10.77	P/FCF	40.31	EPS past 3/5Y	186.88% 98.82%	ROIC	10.62%	52W Low	230.05 5.52%	Perf 3Y	-18.71%
Dividend Est.	-	EV/EBITDA	32.08	Sales past 3/5Y	23.54% 22.92%	Gross Margin	72.11%	Volatility	3.66% 3.36%	Perf 5Y	-16.23%
Dividend TTM	-	EV/Sales	6.88	EPS Y/Y TTM	-41.72%	Oper. Margin	17.32%	ATR (14)	8.78	Perf 10Y	872.13%
Dividend Ex-Date	-	Quick Ratio	2.14	Sales Y/Y TTM	27.12%	Profit Margin	9.76%	RSI (14)	30.91	Recom	1.47
Dividend Gr. 3/5Y	- -	Current Ratio	2.83	EPS Q/Q	14.88%	SMA20	-6.47%	Beta	1.43	Target Price	373.28
Payout	0.00%	Debt/Eq	0.75	Sales Q/Q	29.86%	SMA50	-12.85%	Rel Volume	0.93	Prev Close	240.82
Employees	3900	LT Debt/Eq	0.68	Earnings	Feb 18 BMO	SMA200	-20.33%	Avg Volume	834.06K	Price	242.74
IPO	May 15, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.75% 4.11%	Trades		Volume	776,046	Change	0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Resumed	TD Cowen	Hold	$294
Jan-12-26	Downgrade	Barclays	Overweight → Equal Weight	$274
Dec-16-25	Initiated	Evercore ISI	Outperform	$370
Nov-19-25	Upgrade	UBS	Neutral → Buy	$400
Oct-21-25	Resumed	Stifel	Buy	$370
Sep-08-25	Resumed	Oppenheimer	Outperform	$365
Jun-16-25	Initiated	Truist	Buy	$365
May-30-25	Initiated	Goldman	Buy	$380
May-13-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$350
Apr-29-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Mar-06-25	Initiated	RBC Capital Mkts	Outperform	$340
Nov-06-24	Initiated	Bernstein	Outperform	$300
May-30-24	Initiated	Redburn Atlantic	Buy	$235
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$200
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform	$180 → $238
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$185 → $234
Oct-02-23	Upgrade	Jefferies	Hold → Buy	$260 → $240
Aug-21-23	Upgrade	Citigroup	Neutral → Buy	$273 → $265
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral	$320 → $219
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$343

Show Previous Ratings

Feb-15-26 06:53AM	Insulet Corporation (PODD) Announces Strategic Expansion and Supply Agreement Update (Insider Monkey)
Feb-13-26 04:36PM	Analyst Report: DexCom, Inc. (Morningstar Research)
11:26AM	Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market (PR Newswire)
Feb-12-26 09:15AM	Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-11-26 10:00AM	Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
07:40AM	Loading…
Feb-10-26 07:40AM	Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates (Zacks)
Feb-05-26 07:00AM	Insulet Launches Omnipod 5 and Omnipod Discover in the Middle East to Transform Diabetes Care (Business Wire)
Feb-02-26 07:50PM	Insulet Corporation (PODD): A Bull Case Theory (Insider Monkey)
Jan-30-26 02:31PM	Reasons Why Hedge Funds Favor Insulet Corp (PODD) (Insider Monkey)
Jan-29-26 09:08PM	Analyst Report: Insulet Corporation (Morningstar Research)
Jan-27-26 09:37AM	Target upgraded, Stryker downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Affirm Holdings, Alcoa, Block, Coinbase Global,CoreWeave, Datadog, Intuitive Surgical, and More (24/7 Wall St.)
Jan-26-26 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
Jan-23-26 07:30PM	Analyst Report: DexCom, Inc. (Morningstar Research)
Jan-22-26 08:59PM	Analyst Report: DexCom, Inc. (Morningstar Research)
08:24AM	Loading…
08:24AM	What You Need To Know Ahead of Insulets Earnings Release (Barchart)
Jan-21-26 05:00AM	BVI appoints Jim Hollingshead as CEO (MedTech Dive)
Jan-20-26 07:20PM	Is Insulet (PODD) the Future of Diabetes Management? (Motley Fool)
Jan-15-26 05:26AM	JPM26: Insulet presents optimistic growth plan heading into 2026 (Medical Device Network)
Jan-14-26 12:53PM	Bernstein Reduces Firm's PT on Insulet (PODD) Stock (Insider Monkey)
Jan-12-26 09:49AM	Netflix initiated, Palantir upgraded: Wall Street's top analyst calls (The Fly)
Jan-09-26 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
06:00AM	Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 (Business Wire)
Jan-08-26 09:33AM	What Provides InsuletCorp. (PODD) With a Durable Competitive Advantage? (Insider Monkey)
Jan-06-26 07:00AM	Insulet Redefines Diabetes at CES with "Liveable Technology" - A New Frontier in Human-Centered Connected Health (Business Wire)
Jan-02-26 07:35AM	Is This the Right Time to Add PBH Stock to Your Portfolio? (Zacks)
07:34AM	Is it the Right Time to Add Insulet Stock to Your Portfolio? (Zacks)
Dec-31-25 04:54AM	Best Growth Stocks to Buy for December 31st (Zacks)
Dec-30-25 08:06AM	Should Myriad Genetics Stock Stay in Your Portfolio Right Now? (Zacks)
07:33AM	Reasons to Add Cooper Companies Stock to Your Portfolio Now (Zacks)
07:32AM	Loading…
07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
Dec-29-25 08:52AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio Now (Zacks)
Dec-26-25 12:45PM	3 Reasons Growth Investors Will Love Insulet (PODD) (Zacks)
07:49AM	Should You Continue to Hold BRKR Stock in Your Portfolio? (Zacks)
07:18AM	Reasons to Retain Baxter International Stock in Your Portfolio Now (Zacks)
07:17AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Dec-24-25 08:36AM	Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
02:08PM	Abbott Stock May Benefit Following Volt PFA's FDA Approval (Zacks)
Dec-22-25 09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
08:42AM	Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 (Insider Monkey)
07:49AM	TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch (Zacks)
01:50AM	Medtronics diabetes spinoff MiniMed files for IPO (MedTech Dive)
Dec-19-25 09:09AM	National Vision Stock Surges 154.6% in a Year: What's Driving it? (Zacks)
Dec-18-25 08:36AM	Should You Continue to Hold CRL Stock in Your Portfolio for Now? (Zacks)
07:45AM	Should Investors Hold Chemed Stock in Their Portfolio Now? (Zacks)
Dec-17-25 07:55AM	Should You Retain Teleflex Stock in Your Portfolio Now? (Zacks)
Dec-16-25 10:32AM	Is Insulet Stock Underperforming the Nasdaq? (Barchart)
07:58AM	Is Phibro Animal Health Stock a Smart Addition to Your Portfolio Now? (Zacks)
07:47AM	TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio (Zacks)
07:00AM	Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-15-25 07:54AM	4 Medical Device Stocks to Buy for Healthy Returns in 2026 (Zacks)
07:00AM	Insulet Expands Omnipod U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future (Business Wire)
Dec-11-25 08:09AM	Should You Continue to Hold EW Stock in Your Portfolio? (Zacks)
Dec-10-25 12:45PM	Here is Why Growth Investors Should Buy Insulet (PODD) Now (Zacks)
Dec-08-25 10:34PM	Patient Monitoring Stocks Q3 In Review: Insulet (NASDAQ:PODD) Vs Peers (StockStory)
07:56AM	PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements (Zacks)
Dec-04-25 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
08:34AM	Here's Why You Should Add CONMED Stock to Your Portfolio Now (Zacks)
07:00AM	Insulet Announces FDA 510(k) Clearance of Omnipod 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience (Business Wire)
Dec-01-25 11:34PM	2 Growth Stocks with Explosive Upside and 1 We Find Risky (StockStory) -5.00%
Nov-24-25 12:45PM	Looking for a Growth Stock? 3 Reasons Why Insulet (PODD) is a Solid Choice (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
05:47AM	Insulet unveils plans for new diabetes devices (MedTech Dive)
05:15AM	Zacks.com featured highlights include Insulet, Sandisk and O-I Glass (Zacks)
Nov-21-25 06:36PM	Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know (StockStory) +5.84%
Nov-20-25 12:30PM	Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day (Business Wire) -9.66%
07:56AM	Insulet Stock: Is Wall Street Bullish or Bearish? (Barchart)
07:03AM	3 Stocks With Upgraded Broker Ratings to Buy for Solid Returns (Zacks)
Nov-19-25 01:45PM	Medtronic Stock Sees RS Rating Pumps Higher (Investor's Business Daily)
09:44AM	DoorDash, Baidu upgraded: Wall Street's top analyst calls (The Fly)
Nov-18-25 11:03PM	3 Reasons We Love Insulet (PODD) (StockStory)
09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
09:31AM	Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs (Zacks)
04:01AM	Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion (Zacks)
Nov-17-25 10:23AM	Do Options Traders Know Something About Insulet Stock We Don't? (Zacks)
09:20AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks)
Nov-13-25 12:20PM	Why Insulet (PODD) Might be Well Poised for a Surge (Zacks)
12:06PM	The Wild Ride That Sent IBD Stock Of The Day Insulet Into An Early Breakout (Investor's Business Daily)
10:00AM	Best Momentum Stocks to Buy for Nov. 13 (Zacks)
08:46AM	Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand (Zacks)
05:09AM	New Strong Buy Stocks for Nov. 13: PODD, PRAA, and More (Zacks)
Nov-12-25 05:54AM	Zacks.com featured highlights include Insulet, Celestica and Innodata (Zacks)
Nov-11-25 11:37PM	1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds (StockStory)
03:00PM	3 Top Momentum Stocks to Buy as U.S. Shutdown Nears End (Zacks)
Nov-10-25 12:00PM	Insulet (PODD) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-07-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD) (Zacks)
09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-06-25 05:10PM	Analyst Report: Insulet Corporation (Morningstar Research)
04:06PM	Insulet Stock Goes On A Wild Journey Following Its Beat-And-Raise Quarter (Investor's Business Daily)
11:42AM	Insulet Sheds Early Gains, Sinking Despite Its Broad Omnipod Beat (Investor's Business Daily)
09:30AM	Insulet (PODD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:43AM	Insulet Rises As Broad Omnipod Growth Stokes Beat-And-Raise Quarter (Investor's Business Daily)
07:40AM	Insulet (PODD) Q3 Earnings and Revenues Beat Estimates (Zacks)
06:45AM	Insulet's (NASDAQ:PODD) Q3: Strong Sales (StockStory)
06:35AM	Insulet: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Insulet Reports Third Quarter 2025 Results (Business Wire)
Nov-04-25 10:20PM	Earnings To Watch: Insulet (PODD) Reports Q3 Results Tomorrow (StockStory)
02:09PM	Final Trades: Insulet Corp, Uber and Apollo Global (CNBC TV)
09:15AM	Ahead of Insulet (PODD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Frederick Wayne A.I.	Director	Dec 15 '25	Sale	293.09	1,851	542,510	2,158	Dec 16 04:04 PM
Frederick Wayne A.I.	Director	Dec 15 '25	Proposed Sale	293.09	1,851	542,500		Dec 15 03:03 PM
STONESIFER TIMOTHY C.	Director	Dec 05 '25	Buy	311.73	962	299,884	4,591	Dec 08 04:02 PM
Manea Dan	Former Officer	Nov 26 '25	Proposed Sale	326.64	4,475	1,461,716		Nov 26 04:31 PM
Manea Dan	Former Officer	Nov 24 '25	Proposed Sale	340.95	2,306	786,228		Nov 24 04:06 PM
Manea Dan	Former Officer	Sep 16 '25	Proposed Sale	337.73	1,347	454,920		Sep 16 01:21 PM
Singh Prem	SVP, Global Operations	Sep 08 '25	Sale	347.49	687	238,726	3,456	Sep 09 04:19 PM
Cousin Laetitia	SVP, Reg, Quality & Compliance	Sep 08 '25	Option Exercise	241.10	797	192,160	4,687	Sep 09 04:16 PM
Cousin Laetitia	SVP, Reg, Quality & Compliance	Sep 08 '25	Sale	348.81	797	278,002	3,890	Sep 09 04:16 PM
Cousin Laetitia	Officer	Sep 08 '25	Proposed Sale	348.81	797	278,000		Sep 08 02:07 PM
Singh Prem	Officer	Sep 08 '25	Proposed Sale	347.48	687	238,718		Sep 08 01:31 PM
Benjamin Eric	EVP, CPXO	Aug 21 '25	Sale	332.23	4,263	1,416,296	16,736	Aug 22 04:16 PM
Benjamin Eric	Officer	Aug 21 '25	Proposed Sale	332.23	4,263	1,416,296		Aug 21 10:21 AM
Singh Prem	SVP, Global Operations	Aug 07 '25	Option Exercise	271.28	1,343	364,325	5,486	Aug 08 04:03 PM
Singh Prem	SVP, Global Operations	Aug 07 '25	Sale	320.00	1,343	429,760	4,143	Aug 08 04:03 PM
Singh Prem	Officer	Aug 07 '25	Proposed Sale	320.00	1,343	429,760		Aug 07 11:35 AM
Singh Prem	SVP, Global Operations	Jun 13 '25	Option Exercise	166.62	1,257	209,441	6,470	Jun 16 04:18 PM
Singh Prem	SVP, Global Operations	Jun 13 '25	Sale	300.05	2,327	698,216	4,143	Jun 16 04:18 PM
Manea Dan	SVP, Chief HR Officer	Jun 13 '25	Sale	300.05	1,300	390,065	9,090	Jun 16 04:16 PM
Singh Prem	Officer	Jun 13 '25	Proposed Sale	300.05	2,327	698,216		Jun 13 10:15 AM
Manea Dan	Officer	Jun 13 '25	Proposed Sale	300.05	1,300	390,065		Jun 13 09:45 AM
BORIO LUCIANA	Director	Jun 09 '25	Sale	305.73	481	147,056	3,087	Jun 10 04:17 PM
BORIO LUCIANA	Director	Jun 09 '25	Proposed Sale	305.72	481	147,054		Jun 09 01:08 PM
Hollingshead James	Former Officer	May 16 '25	Proposed Sale	323.10	15,605	5,041,964		May 16 04:40 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Option Exercise	95.43	5,278	503,680	28,458	May 15 04:25 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Sale	318.47	5,278	1,680,885	23,180	May 15 04:25 PM
Hopfield Jessica	Director	May 13 '25	Option Exercise	28.87	5,235	151,134	32,152	May 14 04:15 PM
Hopfield Jessica	Director	May 13 '25	Sale	317.54	5,235	1,662,322	26,917	May 14 04:15 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Option Exercise	92.11	3,001	276,422	23,907	May 14 04:08 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Sale	320.00	3,001	960,320	20,906	May 14 04:08 PM
Kapples John W.	Officer	May 14 '25	Proposed Sale	318.47	5,278	1,680,901		May 14 12:32 PM
Field Mark N	Former Officer	May 13 '25	Proposed Sale	321.31	2,457	789,459		May 13 01:44 PM
Benjamin Eric	Officer	May 13 '25	Proposed Sale	320.00	3,001	960,320		May 13 12:51 PM
Hopfield Jessica	Director	May 13 '25	Proposed Sale	317.54	5,235	1,662,322		May 13 10:19 AM
Frederick Wayne A.I.	Director	Mar 25 '25	Sale	275.00	1,825	501,875	3,231	Mar 26 04:22 PM
Frederick Wayne A.I.	Director	Mar 25 '25	Proposed Sale	275.00	1,825	501,875		Mar 25 10:30 AM
Benjamin Eric	EVP, CPXO	Mar 03 '25	Option Exercise	56.52	5,146	290,873	20,906	Mar 04 04:09 PM

EXAS

Exact Sciences Corp

NVCR

NovoCure Ltd

PODD

Insulet Corporation

Upgrade your FINVIZ experience